BioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019
“The newly passed
Based upon the Company’s analysis of the reimbursement provisions
included in the Medicare Home Infusion Therapy Access Act of 2017 (H.R.
3163/S. 1738) and the Company’s patient census,
Forward-Looking Statements – Safe Harbor
This press release includes statements that may constitute
"forward-looking statements," that involve substantial risks and
uncertainties. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts. In some cases, forward-looking
statements can be identified by words such as "may," "should," "could,"
"anticipate," "estimate," "expect," "project," "outlook," "aim,"
"intend," "plan," "believe," "predict," "potential," "continue" or
comparable terms. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from those
expressed or implied by such forward-looking statements. Investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that actual
results may differ materially from those in the forward-looking
statements as a result of various factors. Important factors that could
cause or contribute to such differences include but are not limited to
risks associated with: the President’s ability to veto the legislation,
the implementation of the legislation and regulations developed in
connection with its implementation, other changes in governmental
reimbursement, government regulation, the impact of any future health
care reform, the Company's ability to grow its core Infusion revenues,
the Company's ability to continue to experience positive results from
its financial improvement plan to reduce operating costs; the Company’s
ability to comply with the covenants in its debt agreements; the success
of the Company’s initiatives to mitigate the impact of the Cures Act on
its business; reductions in federal, state and commercial reimbursement
for the Company's products and services; increased government regulation
related to the health care and insurance industries; as well as the
risks described in the Company's periodic filings with the
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20180209005291/en/
Source:
Investors:
Stephen Deitsch, T:
720-697-5200
Chief Financial Officer & Treasurer
stephen.deitsch@bioscrip.com
or
The
Equity Group
Kalle Ahl, CFA, T: 212-836-9614
kalleahl@equityny.com